Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer
| Autor: | Giovanni Eusepi, Giuseppe Casale, Alice Calvieri, Diana Giannarelli, Maria Rosa Restuccia, Chiara Mastroianni, Ana Dardeli, Caterina Magnani |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Palliative care Cross-sectional study Clinical Decision-Making Fentanyl 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine medicine Mucositis Humans Pain Management Prospective Studies 030212 general & internal medicine Medical prescription Administration Intranasal Aged Pain Measurement Rhinitis Aged 80 and over Stomatitis Morphine business.industry Breakthrough Pain Palliative Care Administration Buccal Cancer Pain General Medicine Middle Aged medicine.disease Analgesics Opioid Cross-Sectional Studies Treatment Outcome Opioid 030220 oncology & carcinogenesis Practice Guidelines as Topic Female Observational study Cancer pain business medicine.drug |
| Zdroj: | Postgraduate Medical Journal. 94:566-570 |
| ISSN: | 1469-0756 0032-5473 |
| DOI: | 10.1136/postgradmedj-2018-135659 |
| Popis: | Background Various options for the pharmacological treatment of breakthrough cancer pain (BTcP) are available. International guidelines on BTcP treatment are not univocal. A tailored treatment should be based on the assessment of different variables such as BTcP characteristics, oral mucositis, chronic rhinitis and a patient’s ability to take medication. Objective The goal of this study is to assess the relationship between these variables and the medication treatment for BTcP in a sample of patients with terminal cancer. Methods A prospective, cross-sectional study was carried out among 1180 patients who were receiving palliative care programmes. Patients were recruited if they had a diagnosis of BTcP and had been prescribed rescue opioids. Variables that might influence the BTcP treatment were assessed. Results One hundred and forty-nine eligible patients were enrolled; 59.1% of patients received short-acting oral morphine (OM), 27.5% transmucosal immediate-release fentanyl (TIRF) and 13.4% parenteral morphine for BTcP treatment. Short-acting OM prescription was related to background pain treatment with OM Conclusion In clinical practice, the factors that most influenced the pharmacological treatment for BTcP were baseline opioid dosage, setting of assistance and self-ability to take medication. Further research is needed to improve the knowledge on tailored BTcP treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|